Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 302 entries
Sorted by: Best Match Show Resources per page
Risk factors, diagnosis, and detection of melanoma.

Current opinion in oncology

MacKie RM.
PMID: 2069997
Curr Opin Oncol. 1991 Apr;3(2):360-3. doi: 10.1097/00001622-199104000-00019.

The incidence of melanoma continues to rise, and accurate figures for this rate of rise in subsets of the population are needed. In addition, it is important to identify occupational groups possibly at greater risk, as well as phenotypic...

Cite
MacKie RM. Risk factors, diagnosis, and detection of melanoma. Curr Opin Oncol. 1991;3(2):360-3doi: 10.1097/00001622-199104000-00019.
MacKie, R. M. (1991). Risk factors, diagnosis, and detection of melanoma. Current opinion in oncology, 3(2), 360-3. https://doi.org/10.1097/00001622-199104000-00019
MacKie, R M. "Risk factors, diagnosis, and detection of melanoma." Current opinion in oncology vol. 3,2 (1991): 360-3. doi: https://doi.org/10.1097/00001622-199104000-00019
MacKie RM. Risk factors, diagnosis, and detection of melanoma. Curr Opin Oncol. 1991 Apr;3(2):360-3. doi: 10.1097/00001622-199104000-00019. PMID: 2069997.
Copy Download .nbib Format: NLM
Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification.

In vivo (Athens, Greece)

Rastrelli M, Tropea S, Rossi CR, Alaibac M.
PMID: 25398793
In Vivo. 2014 Nov-Dec;28(6):1005-11.

This article reviews epidemiology, risk factors, pathogenesis and diagnosis of melanoma. Data on melanoma from the majority of countries show a rapid increase of the incidence of this cancer, with a slowing of the rate of incidence in the...

Cite
Rastrelli M, Tropea S, Rossi CR, et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28(6):1005-11
Rastrelli, M., Tropea, S., Rossi, C. R., & Alaibac, M. (2014). Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In vivo (Athens, Greece), 28(6), 1005-11.
Rastrelli, Marco, et al. "Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification." In vivo (Athens, Greece) vol. 28,6 (2014): 1005-11.
Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014 Nov-Dec;28(6):1005-11. PMID: 25398793.
Copy Download .nbib Format: NLM
BRAF-mutant ctDNA predicts outcomes.

Nature reviews. Clinical oncology

Sidaway P.
PMID: 33654307
Nat Rev Clin Oncol. 2021 May;18(5):258. doi: 10.1038/s41571-021-00494-0.

No abstract available.

Cite
Sidaway P. BRAF-mutant ctDNA predicts outcomes. Nat Rev Clin Oncol. 2021;18(5):258doi: 10.1038/s41571-021-00494-0.
Sidaway, P. (2021). BRAF-mutant ctDNA predicts outcomes. Nature reviews. Clinical oncology, 18(5), 258. https://doi.org/10.1038/s41571-021-00494-0
Sidaway, Peter. "BRAF-mutant ctDNA predicts outcomes." Nature reviews. Clinical oncology vol. 18,5 (2021): 258. doi: https://doi.org/10.1038/s41571-021-00494-0
Sidaway P. BRAF-mutant ctDNA predicts outcomes. Nat Rev Clin Oncol. 2021 May;18(5):258. doi: 10.1038/s41571-021-00494-0. PMID: 33654307.
Copy Download .nbib Format: NLM
Myosteatosis is prognostic in metastatic melanoma treated with nivolumab.

Clinical nutrition ESPEN

Youn S, Reif R, Chu MP, Smylie M, Walker J, Eurich DT, Ghosh S, Sawyer MB.
PMID: 33745604
Clin Nutr ESPEN. 2021 Apr;42:348-353. doi: 10.1016/j.clnesp.2021.01.009. Epub 2021 Jan 20.

BACKGROUND: While immunotherapy agents have improved outcomes in metastatic melanoma (MM), predictive biomarkers in these patients are lacking. Parameters identified from body composition analysis, such as low SMD (also termed myosteatosis), may prognosticate MM patients on immunotherapy.METHODS: In this...

Cite
Youn S, Reif R, Chu MP, et al. Myosteatosis is prognostic in metastatic melanoma treated with nivolumab. Clin Nutr ESPEN. 2021;42:348-353doi: 10.1016/j.clnesp.2021.01.009.
Youn, S., Reif, R., Chu, M. P., Smylie, M., Walker, J., Eurich, D. T., Ghosh, S., & Sawyer, M. B. (2021). Myosteatosis is prognostic in metastatic melanoma treated with nivolumab. Clinical nutrition ESPEN, 42348-353. https://doi.org/10.1016/j.clnesp.2021.01.009
Youn, Susie, et al. "Myosteatosis is prognostic in metastatic melanoma treated with nivolumab." Clinical nutrition ESPEN vol. 42 (2021): 348-353. doi: https://doi.org/10.1016/j.clnesp.2021.01.009
Youn S, Reif R, Chu MP, Smylie M, Walker J, Eurich DT, Ghosh S, Sawyer MB. Myosteatosis is prognostic in metastatic melanoma treated with nivolumab. Clin Nutr ESPEN. 2021 Apr;42:348-353. doi: 10.1016/j.clnesp.2021.01.009. Epub 2021 Jan 20. PMID: 33745604.
Copy Download .nbib Format: NLM
Information Patients With Melanoma Spontaneously Report About Health-Related Quality of Life on Web-Based Forums: Case Study.

Journal of medical Internet research

Kalf RRJ, Delnoij DMJ, Ryll B, Bouvy ML, Goettsch WG.
PMID: 34878994
J Med Internet Res. 2021 Dec 07;23(12):e27497. doi: 10.2196/27497.

BACKGROUND: There is a general agreement on the importance of health-related quality of life (HRQoL). This type of information is becoming increasingly important for the value assessment of health technology assessment agencies in evaluating the benefits of new health...

Cite
Kalf RRJ, Delnoij DMJ, Ryll B, et al. Information Patients With Melanoma Spontaneously Report About Health-Related Quality of Life on Web-Based Forums: Case Study. J Med Internet Res. 2021;23(12):e27497doi: 10.2196/27497.
Kalf, R. R. J., Delnoij, D. M. J., Ryll, B., Bouvy, M. L., & Goettsch, W. G. (2021). Information Patients With Melanoma Spontaneously Report About Health-Related Quality of Life on Web-Based Forums: Case Study. Journal of medical Internet research, 23(12), e27497. https://doi.org/10.2196/27497
Kalf, Rachel R J, et al. "Information Patients With Melanoma Spontaneously Report About Health-Related Quality of Life on Web-Based Forums: Case Study." Journal of medical Internet research vol. 23,12 (2021): e27497. doi: https://doi.org/10.2196/27497
Kalf RRJ, Delnoij DMJ, Ryll B, Bouvy ML, Goettsch WG. Information Patients With Melanoma Spontaneously Report About Health-Related Quality of Life on Web-Based Forums: Case Study. J Med Internet Res. 2021 Dec 07;23(12):e27497. doi: 10.2196/27497. PMID: 34878994.
Copy Download .nbib Format: NLM
Evolving treatment landscape: 18 years of managing melanoma in a single patient.

BMJ case reports

Biosse-Duplan G, Murphy S, Durrani A, Corrie P.
PMID: 34728513
BMJ Case Rep. 2021 Nov 02;14(11). doi: 10.1136/bcr-2021-246070.

A 57-year-old woman diagnosed with primary melanoma was managed with a wide variety of treatments over 18 years. Given her long history of disease, the array of therapies she has received range from those no longer recommended to those...

Cite
Biosse-Duplan G, Murphy S, Durrani A, et al. Evolving treatment landscape: 18 years of managing melanoma in a single patient. BMJ Case Rep. 2021;14(11)doi: 10.1136/bcr-2021-246070.
Biosse-Duplan, G., Murphy, S., Durrani, A., & Corrie, P. (2021). Evolving treatment landscape: 18 years of managing melanoma in a single patient. BMJ case reports, 14(11), . https://doi.org/10.1136/bcr-2021-246070
Biosse-Duplan, Garance, et al. "Evolving treatment landscape: 18 years of managing melanoma in a single patient." BMJ case reports vol. 14,11 (2021). doi: https://doi.org/10.1136/bcr-2021-246070
Biosse-Duplan G, Murphy S, Durrani A, Corrie P. Evolving treatment landscape: 18 years of managing melanoma in a single patient. BMJ Case Rep. 2021 Nov 02;14(11). doi: 10.1136/bcr-2021-246070. PMID: 34728513; PMCID: PMC8565563.
Copy Download .nbib Format: NLM
Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Cavalieri S, Ronchi S, Barcellini A, Bonora M, Vischioni B, Vitolo V, Villa R, Del Vecchio M, Licitra L, Orlandi E.
PMID: 34506831
Radiother Oncol. 2021 Nov;164:1-5. doi: 10.1016/j.radonc.2021.08.021. Epub 2021 Sep 08.

We analyzed CTCAE adverse events of sequential Carbon Ion radiotherapy (CIRT) and immune checkpoint inhibitors (ICIs) in advanced melanoma patients. The frequencies of early and late adverse events (AEs) were 100% and 82% of patients, respectively. The frequency of...

Cite
Cavalieri S, Ronchi S, Barcellini A, et al. Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. Radiother Oncol. 2021;164:1-5doi: 10.1016/j.radonc.2021.08.021.
Cavalieri, S., Ronchi, S., Barcellini, A., Bonora, M., Vischioni, B., Vitolo, V., Villa, R., Del Vecchio, M., Licitra, L., & Orlandi, E. (2021). Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1641-5. https://doi.org/10.1016/j.radonc.2021.08.021
Cavalieri, Stefano, et al. "Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 164 (2021): 1-5. doi: https://doi.org/10.1016/j.radonc.2021.08.021
Cavalieri S, Ronchi S, Barcellini A, Bonora M, Vischioni B, Vitolo V, Villa R, Del Vecchio M, Licitra L, Orlandi E. Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. Radiother Oncol. 2021 Nov;164:1-5. doi: 10.1016/j.radonc.2021.08.021. Epub 2021 Sep 08. PMID: 34506831.
Copy Download .nbib Format: NLM
[Melanoma in medical practice].

Concours medical

MEYER J.
PMID: 13127356
Concours Med. 1954 Jan 16;76(3):207-11.

No abstract available.

Cite
MEYER J. Les tumeurs mélaniques en pratique médicale. [Melanoma in medical practice]. Concours Med. 1954;76(3):207-11
MEYER, J. (1954). Les tumeurs mélaniques en pratique médicale. [Melanoma in medical practice]. Concours medical, 76(3), 207-11.
MEYER, J. "Les tumeurs mélaniques en pratique médicale." [Melanoma in medical practice]. Concours medical vol. 76,3 (1954): 207-11.
MEYER J. Les tumeurs mélaniques en pratique médicale. [Melanoma in medical practice]. Concours Med. 1954 Jan 16;76(3):207-11. Undetermined. PMID: 13127356.
Copy Download .nbib Format: NLM
Is melanoma curable? Long-term survival in consecutive cases of melanoma.

Journal of the American Medical Women's Association

FIGUEREDO AV.
PMID: 13664564
J Am Med Womens Assoc. 1959 Jun;14(6):493-8.

No abstract available.

Cite
FIGUEREDO AV. Is melanoma curable? Long-term survival in consecutive cases of melanoma. J Am Med Womens Assoc. 1959;14(6):493-8
FIGUEREDO, A. V. (1959). Is melanoma curable? Long-term survival in consecutive cases of melanoma. Journal of the American Medical Women's Association, 14(6), 493-8.
FIGUEREDO, A V. "Is melanoma curable? Long-term survival in consecutive cases of melanoma." Journal of the American Medical Women's Association vol. 14,6 (1959): 493-8.
FIGUEREDO AV. Is melanoma curable? Long-term survival in consecutive cases of melanoma. J Am Med Womens Assoc. 1959 Jun;14(6):493-8. PMID: 13664564.
Copy Download .nbib Format: NLM
Melanocarcinoma of childhood. Report of a case.

Archives of surgery (Chicago, Ill. : 1960)

HOAGLAND PW, HUGHES CW.
PMID: 13714746
Arch Surg. 1960 Dec;81:957-60. doi: 10.1001/archsurg.1960.01300060103020.

No abstract available.

Cite
HOAGLAND PW, HUGHES CW. Melanocarcinoma of childhood. Report of a case. Arch Surg. 1960;81:957-60doi: 10.1001/archsurg.1960.01300060103020.
HOAGLAND, P. W., & HUGHES, C. W. (1960). Melanocarcinoma of childhood. Report of a case. Archives of surgery (Chicago, Ill. : 1960), 81957-60. https://doi.org/10.1001/archsurg.1960.01300060103020
HOAGLAND, P W, and HUGHES, C W. "Melanocarcinoma of childhood. Report of a case." Archives of surgery (Chicago, Ill. : 1960) vol. 81 (1960): 957-60. doi: https://doi.org/10.1001/archsurg.1960.01300060103020
HOAGLAND PW, HUGHES CW. Melanocarcinoma of childhood. Report of a case. Arch Surg. 1960 Dec;81:957-60. doi: 10.1001/archsurg.1960.01300060103020. PMID: 13714746.
Copy Download .nbib Format: NLM
Understanding melanoma.

Imprint

[No authors listed]
PMID: 9505598
Imprint. 1998 Jan;45(1):14.

No abstract available.

Cite
Understanding melanoma. Imprint. 1998;45(1):14
(1998). Understanding melanoma. Imprint, 45(1), 14.
"Understanding melanoma." Imprint vol. 45,1 (1998): 14.
Understanding melanoma. Imprint. 1998 Jan;45(1):14. PMID: 9505598.
Copy Download .nbib Format: NLM
STATE University of Iowa College of Medicine; clinical pathologic conference.

Journal. Iowa State Medical Society

[No authors listed]
PMID: 13109296
J Iowa State Med Soc. 1953 Nov;43(11):466-70.

No abstract available.

Cite
STATE University of Iowa College of Medicine; clinical pathologic conference. J Iowa State Med Soc. 1953;43(11):466-70
(1953). STATE University of Iowa College of Medicine; clinical pathologic conference. Journal. Iowa State Medical Society, 43(11), 466-70.
"STATE University of Iowa College of Medicine; clinical pathologic conference." Journal. Iowa State Medical Society vol. 43,11 (1953): 466-70.
STATE University of Iowa College of Medicine; clinical pathologic conference. J Iowa State Med Soc. 1953 Nov;43(11):466-70. PMID: 13109296.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 302 entries